Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients.

ABSTRACT: Background: Neprilysin inhibition has demonstrated impressive benefits in heart failure treatment, and is the current focus of interest in cardiovascular (CV) and kidney diseases. However, the role of circulating neprilysin as a biomarker for CV events is unclear in hemodialysis (HD) patients. Methods: A total of 439 HD patients from the K-cohort were enrolled from June 2016 to April 2019. The plasma neprilysin level and echocardiographic findings at baseline were examined. The patients were prospectively followed up to assess the primary endpoint (composite of CV events and cardiac events). Results: Plasma neprilysin level was positively correlated with left ventricular (LV) mass index, LV end-systolic volume, and LV end-diastolic volume. Multivariate linear regressio

SUBMITTER: Hwang HS 

PROVIDER: S-EPMC8239158 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature